The short version of N-terminal modification fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-20 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
== History == In 2009, Zimbabwe Cricket announced a major restructure of domestic cricket in Zimbabwe and the traditional provincial sides were replaced with regional franchises. Midlands was renamed Mid West Rhinos and based in the mining town of Kwekwe. With the new franchise system in place the season got under way on 14 September 2009. Current captain Vusimuzi Sibanda was the first person to score a hundred under the new 'Mid West Rhinos' name as they convincingly beat the newly titled Matabeleland Tuskers by 135 runs. Sadly for the Rhinos, the season ended in a tense draw that saw the Mashonaland Eagles triumph narrowly. The 2010/11 season was a promising for the Rhinos as they retained the services of a number of top Zimbabwe players. Once again, they failed to win any trophies despite winning 4 games and losing only 2 in the newly branded Castle Logan Cup. Throughout the following seasons, the Rhinos have had many successes but failed to win any trophies. Despite a delay to the start of the 2014/15 season, the season began with the Mid West Rhinos tipped to be one of the stronger sides in both the four-day and one-day competitions. However, amid off-field issues affecting both the Rhinos and Zimbabwean cricket as a whole, the first part of the season saw mixed results. The only win for the Rhinos in the Logan Cup before Christmas came as a result of a poor performance by the Mashonaland Eagles in the season opener.
Bacterial alginates are useful for the production of micro- or nanostructures suitable for medical applications. Sodium alginate (NaC6H7O6) is the sodium salt of alginic acid. Sodium alginate is a gum. Potassium alginate (KC6H7O6) is the potassium salt of alginic acid. Calcium alginate (CaC12H14O12) is the calcium salt of alginic acid. It is made by replacing the sodium ion in sodium alginate with a calcium ion (ion exchange).
=== New books === Thomas Charles - Geiriadur Ysgrythyrol Richard Colt Hoare - Life of Giraldus Theophilus Jones - History of the County of Brecknock, vol. 1 Titus Lewis - A Welsh — English Dictionary, Geiriadur Cymraeg a Saesneg Robert Southey - Madoc
Sources: en.wikipedia.org
== External links == Peptide+Elongation+Factor+Tu at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P49410 (Elongation factor Tu, mitochondrial) at the PDBe-KB.
. In conventional chromatography, separation of similar compounds can be improved by gradient elution. In MEKC, however, techniques must be used to extend the elution range to separate strongly retained analytes. Elution ranges can be extended by several techniques including the use of organic modifiers, cyclodextrins, and mixed micelle systems. Short-chain alcohols or acetonitrile can be used as organic modifiers that decrease
Intentional mummification in pre-Columbian Mexico was practiced by the Aztec culture. These bodies are collectively known as Aztec mummies. Genuine Aztec mummies were "bundled" in a woven wrap and often had their faces covered by a ceremonial mask. Public knowledge of Aztec mummies increased due to traveling exhibits and museums in the 19th and 20th centuries, though these bodies were typically naturally desiccated remains and not actually the mummies associated with Aztec culture. Natural mummification has been known to occur in several places in Mexico; this includes the mummies of Guanajuato. A collection of these mummies, most of which date to the late 19th century, have been on display at El Museo de las Momias in the city of Guanajuato since 1970. The museum claims to have the smallest mummy in the world on display (a mummified fetus). It was thought that minerals in the soil had the preserving effect, however it may rather be due to the warm, arid climate. Mexican mummies are also on display in the small town of Encarnación de Díaz, Jalisco.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.